Kyle Doherty

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

OncLive outlines some of the most notable new agents and combinations to earn FDA approval in 2025, including the topline data supporting these decisions.

Oncology Fellows spotlights fellows who received research fellowship grants during the 2025 ESMO Congress.

The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.

Guillermo Garcia-Manero, MD, discusses the phase 3 GLORA-4 study of lisaftoclax plus azacitidine in higher-risk MDS.

Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.

Raji Shameem, MD, discusses the continuing evolution of the frontline treatment landscape of metastatic pancreatic cancer.

Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.

In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.

Rahul Banerjee, MD, FACP, discusses the ongoing investigations of mezigdomide and CELMoDs in multiple myeloma.

The FDA has granted fast track designation to gamgertamig for autoimmune hemolytic anemia and immune thrombocytopenia.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Elena Elimova, MD, discusses findings for zanidatamab chemotherapy with/without tislelizumab in advanced HER2-positive gastroesophageal adenocarcinoma.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Mark A. Socinski, MD, and Martin F. Dietrich, MD, PhD, discuss molecular testing methodologies for NSCLC.

David P. Carbone, MD, PhD, and Niels Reinmuth, MD, PhD, discussed the landscapes of biomarker testing and screening in NSCLC.

Treatment discontinuation with first-line BTK inhibitors was higher in the real-world setting vs the clinical trial setting among patients with CLL/SLL.

Virginia Kaklamani, MD, discusses data from the ELEVATE study of elacestrant as a combination component in ER+/HER2- breast cancer.

An international group of thoracic oncology specialists reviewed key updates in first-line NSCLC from the 2025 ESMO Asia Congress.

Experts in the field of CLL/SLL discussed the role of BTK inhibitors and degraders in R/R CLL/SLL during an OncLive Scientific Interchange and Workshop.

Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D-mutated locally advanced or metastatic NSCLC.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Obinutuzumab plus zanubrutinib, pomalidomide, and venetoclax produced high response rates in high-risk MCL.

Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.

Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.